Therefore, to improve the sensitivity of ovarian cancer cells to platinum-based chemotherapy, targeting the PI3K/ATK/mTOR signal pathway has emerged as one of the major therapeutic strategies [19, 20]. This evidence concerns the gene MTOR and ovarian carcinoma.